Compare Abeona Therapeutics Inc (ABEO) vs Peloton Interactive Inc (PTON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Peloton Interactive Inc — how do they compare? Abeona Therapeutics Inc trades at $6.69 (market cap $373.32M), while Peloton Interactive Inc trades at $5.71 (market cap $2.52B). The key difference: Peloton Interactive Inc is far larger — about 6.8× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Peloton Interactive Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | PTON | |
|---|---|---|
Market Cap | $373.32M | $2.52B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $9.00 |
52-Week Low | $4.17 | $3.71 |
Enterprise Value | $228.22M | $3.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Peloton (PTON) trades at $5.82, up 1.22% on the day, with a bullish technical signal from moving averages. The company shows improving fundamentals, with operating cash flow turning positive to $333 million in 2025 and net losses narrowing significantly. Recent news highlights a potential turnaround, including inclusion in the S&P SmallCap 600 index and the appointment of a new CFO.
The outlook is cautiously optimistic as Peloton aims for profitability, but risks remain from high debt and revenue declines. Analyst consensus is a Buy with a $7.50 price target, suggesting 29% upside, though execution on growth initiatives is critical for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →
